TEVA-CHLORPROMAZINE TABLET

Nazione: Canada

Lingua: inglese

Fonte: Health Canada

Principio attivo:

CHLORPROMAZINE (CHLORPROMAZINE HYDROCHLORIDE)

Commercializzato da:

TEVA CANADA LIMITED

Codice ATC:

N05AA01

INN (Nome Internazionale):

CHLORPROMAZINE

Dosaggio:

25.0MG

Forma farmaceutica:

TABLET

Composizione:

CHLORPROMAZINE (CHLORPROMAZINE HYDROCHLORIDE) 25.0MG

Via di somministrazione:

ORAL

Confezione:

100/500/1000

Tipo di ricetta:

Prescription

Area terapeutica:

PHENOTHIAZINES

Dettagli prodotto:

Active ingredient group (AIG) number: 0106167006; AHFS:

Stato dell'autorizzazione:

APPROVED

Data dell'autorizzazione:

2011-03-08

Scheda tecnica

_TEVA-CHLORPROMAZINE _
_ _
_Product Monograph _
_Page 1 of 18_
PRODUCT MONOGRAPH
PR
TEVA-CHLORPROMAZINE
Chlorpromazine Hydrochloride Tablets
25 mg, 50 mg and 100 mg
Teva Standard
Antipsychotic–Antiemetic
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
Canada, M1B 2K9
www.tevacanada.com
Date of Preparation:
December 11, 2012
SUBMISSION CONTROL NO: 154593
_TEVA-CHLORPROMAZINE _
_ _
_Product Monograph _
_Page 2 of 18_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND ADMINISTRATION
..............................................................................10
OVERDOSAGE
................................................................................................................11
ACTION AND CLINICAL PHARMACOLOGY
............................................................11
STORAGE AND STABILITY
..........................................................................................12
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................12
PART II: SCIENTIFIC INFORMATION
...............................................................................13
PHARMACEUTICAL INFORMATION
..........................................................................13
REFERENCES
..............................................................